Stock EXEL EXELIXIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Exelixis, Inc.

Equities

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
23.71 USD +1.80% Intraday chart for Exelixis, Inc. +3.67% -1.17%
Apr. 12 North American Morning Briefing : Big Banks Kick -2- DJ
Apr. 11 Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25 MT

Business Summary

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Number of employees: 1,310

Sales per Business

USD in Million2022Weight2023Weight Delta
Medicines for Difficult-to-treat Cancers
100.0 %
1,611 100.0 % 1,830 100.0 % +13.60%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
89.9 %
1,414 87.8 % 1,646 89.9 % +16.41%
Europe
7.9 %
169 10.5 % 145 7.9 % -14.01%
Japan
2.2 %
29 1.8 % 39 2.2 % +37.47%

Managers

Managers TitleAgeSince
Michael Morrissey CEO
 Chief Executive Officer 63 00-01-31
Christopher Senner DFI
 Director of Finance/CFO 56 15-07-14
Amy Peterson CTO
 Chief Tech/Sci/R&D Officer 57 23-08-22
Dana Aftab CTO
 Chief Tech/Sci/R&D Officer - 97-12-31
Susan T. Hubbard IRC
 Investor Relations Contact - 16-11-30
Stefan Krauss PRN
 Corporate Officer/Principal - 16-12-06
Patrick Haley PRN
 Corporate Officer/Principal 48 09-12-31
Jeffrey Hessekiel LAW
 General Counsel 55 14-02-09
Laura Dillard HRO
 Human Resources Officer - 05-10-31
Peter Lamb PRN
 Corporate Officer/Principal 63 00-09-30

Members of the board

Members of the board TitleAgeSince
Alan Garber BRD
 Director/Board Member 68 04-12-31
Jack Wyszomierski BRD
 Director/Board Member 68 04-01-31
George Poste BRD
 Director/Board Member 79 04-07-31
Stelios Papadopoulos FOU
 Founder 74 94-11-14
Michael Morrissey CEO
 Chief Executive Officer 63 00-01-31
Jacqueline Wright BRD
 Director/Board Member 64 21-12-15
Mary Beckerle BRD
 Director/Board Member 69 Jan. 04
Maria Freire BRD
 Director/Board Member 69 18-04-04
Tomas Jan Heyman BRD
 Director/Board Member 68 23-05-30
Robert Oliver BRD
 Director/Board Member - 23-05-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 294,799,955 288,212,036 ( 97.77 %) 0 97.77 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
11.13 %
33,739,842 11.13 % 801 M $
Vanguard Fiduciary Trust Co.
10.45 %
31,671,090 10.45 % 752 M $
Farallon Capital Management LLC
8.785 %
26,634,500 8.785 % 632 M $
Renaissance Technologies LLC
5.150 %
15,615,716 5.150 % 371 M $
STATE STREET CORPORATION
4.299 %
13,032,818 4.299 % 309 M $
JPMorgan Investment Management, Inc.
2.549 %
7,729,504 2.549 % 183 M $
Geode Capital Management LLC
1.697 %
5,145,318 1.697 % 122 M $
Eaton Vance Management
1.575 %
4,774,731 1.575 % 113 M $
Dimensional Fund Advisors LP
1.504 %
4,560,517 1.504 % 108 M $
Stephens Investment Management Group LLC
1.354 %
4,106,664 1.354 % 97 M $

Company contact information

Exelixis, Inc.

1851 Harbor Bay Parkway

94502, Alameda

+650 837 7000

http://www.exelixis.com
address Exelixis, Inc.(EXEL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Exelixis, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
23.71 USD
Average target price
26.63 USD
Spread / Average Target
+12.33%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
EXELIXIS, INC. Stock Exelixis, Inc.
-1.17% 6.87B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 105B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.5B
ARGENX SE Stock argenx SE
+1.86% 22.19B
BIONTECH SE Stock BioNTech SE
-16.53% 21.33B
GENMAB A/S Stock Genmab A/S
-8.49% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.6B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 14.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 14.09B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 10.99B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. EXEL Stock
  4. Company Exelixis, Inc.